Preview

Российский кардиологический журнал

Расширенный поиск

ВЛИЯНИЕ ПОБОЧНЫХ ЭФФЕКТОВ ИНГИБИТОРОВ АНГИОТЕНЗИН-ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА НА ТАКТИКУ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ

https://doi.org/10.15829/1560-4071-2005-3-79-90

Полный текст:

Об авторах

В. А. Орлов
Российская медицинская академия последипломного образования МЗ и СР РФ
Россия

кафедра клинической фармакологии и терапии



С. Р. Гиляревский
Российская медицинская академия последипломного образования МЗ и СР РФ
Россия
кафедра клинической фармакологии и терапии


Д. М. Урусбиева
Российская медицинская академия последипломного образования МЗ и СР РФ
Россия
кафедра клинической фармакологии и терапии


Л. В. Даурбекова
Российская медицинская академия последипломного образования МЗ и СР РФ
Россия
кафедра клинической фармакологии и терапии


Список литературы

1. Brown N.J., Vaughan D.E. Angiotensin-Converting Enzyme Inhibitors. Circulation 1998; 97: 1411-1420.

2. Zusman R.M. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am. J. Kidney. Dis. 1987; 10(Suppl 1): 13-23.

3. Mira M.L., Silva M.M., Manso C.F. The scavenging of oxygen free radicals by angiotensin converting enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds. Ann. N.Y. Acad. Sci. 1994; 723: 439-441.

4. Ferner R.E. Adverse effects of angiotensin-converting-enzyme inhibitors. Adv. Drug. React. Bull. 1990; 141: 528-531.

5. Warner N.J., Rush J.E. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs. 1988; 35 (Suppl. 5): 89-97.

6. Oster J.R., Materson B.J. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch. Intern. Med. 1992: 152: 704-710.

7. Reid J.L., MacFadyen R.J., Squire I.B., Lees K.R. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am. Heart. J. 1993; 126: 794-797.

8. Webster J. Angiotensin converting enzyme inhibitors in the clinic: first dose hypotension. J. Hypertens. 1994; 5: S27-S30.

9. Yajnik V.H., Vatsraj D.J., Acharya H.K., et al. Ramipril vs captopril in mild to moderate hypertension. J. Assoc. Physicians. India 1994; 42(2): 120-123.

10. Parish R.C., Miller L.J. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf. 1992; 7: 14-31

11. DiBianco R. ACE inhibitors in the treatment of heart failure. Clin. Cardiol. 1990; 13: VII-32-VII-38.

12. ACE inhibitor first dose effect (editorial). Med. J. Aust 1993; 158: 208.

13. Navookarasu N.T., Rahman A.R., Abdullah I. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience. Int. J. Clin. Pract. 1999; 53: 25-30.

14. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet. 1995; 345: 669-685.

15. Desachy A., Normand S., Francois B., et al. Refractory shock after converting enzyme inhibitor administration. Usefulness of angiotensin II. Presse. Med. 2000; 29(13): 696-698.

16. Routledge H.C., Townend J.N. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? Hum. Hypertens. 2001; 15(10): 659-667.

17. Martinez Sanchez C., Henne O., Arceo A., et al. Hemodynamic effects of oral captopril in patients with critical aortic stenosis. Arch. Inst. Cardiol. Мех. 1996; 66(4): 322-330.

18. Weinberg E.O., Schoen F.J., George D., et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1994; 90(3): 1410-1422.

19. Friedrich S.P., Lorell B.H., Rousseau M.F., et al. Intracardiac angiotensin-converting-enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation. 1994; 90(6): 2761-2771.

20. Wynckel A., Ebikili B., Melin J-R., et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am. J. Hypertens. 1998; 11(9): 1080-10S6.

21. Dzau V.J. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. Am. J. Kidney. Dis. 1987; 10: 74-80.

22. Apperloo A.J., de Zeeuw D., de Jong P.E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 1997; 51: 793-797.

23. Dietz R., Nagel F., Osterziel K.J. Angiotensin-converting-enzyme inhibitors and renal function in heart failure. Am. J. Cardiol. 1992; 70: 119C-125C.

24. Knight E.L., Glynn R.J., McIntyre K.M., et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting-enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am. Heart. J. 1999; 138(5 Pt l): 849-855.

25. Flather M.D., Yusuf S., Kinber L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or leftventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000; 355(9215): 1575-1581.

26. Mason N.A. Angiotensin-converting-enzyme inhibitors and renal function. Ann. Pharmacother. 1990; 24(5): 496-505.

27. Hui K.K., Duchin K.L., Kripalani K J., et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin. Pharmacol. Ther. 1991; 49(4): 457-467.

28. Greenbaum R., Zucchelli P., Caspi A., Nouriel H., Paz R., Sclarovsky S., О'Grady P., Yee K.F., Liao W.C., Mangold B. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br. J. Clin. Pharmacol. 2000; 49(1): 23-31.

29. Breyer M.D., Hao C., Qi Z. Cyclooxygenase-2 selective inhibitors and the kidney. Curr. Opin. Crit. Care. 2001; 7(6): 393-400.

30. Harjai K.J., Nunez E., Turgut T., Newman J. Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on re-admission rates in heart failure. Am. J. Cardiol. 2001; 87(4): 483-487.

31. Latini R., Tognoni G., Maggioni A.P., et al. Clinical effects of early angiotensin-converting-enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96, 712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J. Am. Coll. Cardiol. 2000; 35(7): 1801-1807.

32. Armayer G.M., Lopez L.M. Lisinopril: a new angiotensin-converting enzyme inhibitor. Drug. In-tell. Clin. Pharm. 1988; 22: 365-372

33. Persson C.G.A., Draco A.B. Xanthines as airway antiinflammatory drugs. J. Allergy. Clin. Immunol. 1988; 81: 615-616.

34. Lee S.C., Park S.W., Kim D.K., et al. Iron supplementation inhibits cough associated with ACE inhibitors. Hypertension. 2001; 38(2): 166-170.

35. Brown N.J., Nadeau J.H. Does race predispose to angiotensin-associated angioneurotic edema? (letter). Ann. Intern. Med. 1993; 119: 1224.

36. Chan W.K., Chan T.Y., Luk W.K., et al. A high incidence of cough in Chinese subjects treated with angiotensin-converting-enzyme inhibitors. Eur. J. Clin. Pharmacol. 1993; 44: 299-300.

37. Smoger S.H., Sayed M.A. Simultaneous mucosal and small bowel angioedema due to captopril. South. Med. J. 1998; 91(11): 1060-1063.

38. Chase M.P., Fiarman G.S., Scholz F.J., et al. Angioedema of the small bowel due to an angiotensin-converting-enzyme inhibitor. J. Clin. Gastroenterol 2000; 31(3): 254-257.

39. Casato M., Pucillo L.P., Leoni M., et al. Granulocytopenia after combined therapy with interferon and angiotensin-converting-enzyme inhibitors: evidence for a synergistic hematologic toxicity. Am. J. Med. 1995; 99(4): 386-391.

40. Bart B.A., Ertl G., Held P., et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.


Для цитирования:


Орлов В.А., Гиляревский С.Р., Урусбиева Д.М., Даурбекова Л.В. ВЛИЯНИЕ ПОБОЧНЫХ ЭФФЕКТОВ ИНГИБИТОРОВ АНГИОТЕНЗИН-ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА НА ТАКТИКУ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ. Российский кардиологический журнал. 2005;(3):79-90. https://doi.org/10.15829/1560-4071-2005-3-79-90

For citation:


Orlov V.A., Gilyarevsky S.R., Urusbieva D.M., Daurbekova L.V. Adverse effects of ACE inhibitors and cardiovascular treatment tactics. Russian Journal of Cardiology. 2005;(3):79-90. (In Russ.) https://doi.org/10.15829/1560-4071-2005-3-79-90

Просмотров: 30


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)